Clinical Applications of Molecular Subtyping of Pancreatic Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".

Deadline for manuscript submissions: closed (1 July 2024) | Viewed by 5368

Special Issue Editor


E-Mail Website
Guest Editor
Department of Surgery, University of Patras Medical School, 26500 Patras, Greece
Interests: stem cells; pagreatic cancer

Special Issue Information

Dear Colleagues,

Pancreatic cancer is one of the biggest oncological and surgical challenges, for pancreatic malignancies are the fourth leading cause of death in adults and cause an estimated loss of 600,000–915,000 quality-adjusted life years (QALYs). Aggressive tumor growth and late diagnosis are primarily responsible for unfavorable prognosis, and although survival rate has improved in recent decades, it continues to remain low for patients with advanced pancreatic disease. With the evolution of genomics, next generation and whole genome sequencing, we now have an opportunity to tackle the aggressive growth and expansion of pancreatic tumors using novel techniques that might enable personalized treatment of pancreatic cancer patients. Utilization of a molecular taxonomy of pancreatic cancer will inform preclinical and clinical decision-making and assist in the development of novel therapeutic interventions.

This Special Issue is dedicated to publishing research centered around the developments in molecular subtyping of pancreatic cancer, whether related to a novel method, a transcriptomic subtype method or single gene alteration. Research on the practical applications of molecular subtyping in clinical practices, such as decision-making in surgical approaches, correlations with postoperative outcomes, administration of chemotherapy and long-term response, are encouraged. Future perspectives of genome-based subtyping will also be considered, especially regarding pancreatic transplantation where in vivo models of pancreatic transplantation have revealed progression and alteration of PDAC molecular subtypes. Therefore, we cordially invite researchers with experience in the MDT approach for the treatment of pancreatic diseases to share their invaluable insights.

In this Special Issue, original research articles, reviews,  and expert opinions are welcome. Research areas may include (but are not limited to) the following:

  • Implications of pancreatic molecular cancer in pancreatic surgery;
  • Association of postoperative outcomes in different molecular subtypes;
  • Response to systematic therapy according to molecular subtypes;
  • Implications of pancreatic transplant in genomic changes;
  • Use of NGS in pancreatic cancer specimens;
  • Personalized decision-making based on molecular subtyping;
  • New advancements in targeted treatment strategies.

We look forward to receiving your contributions.

Prof. Dr. Ioannis C. Maroulis
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pancreatic cancer
  • pancreatic adenocarcinoma
  • genomic subtyping
  • transcriptomics
  • next generation sequencing
  • pancreatic surgery
  • pancreatic transplantation

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

20 pages, 5318 KiB  
Review
Targeting Perineural Invasion in Pancreatic Cancer
by Ingrid Garajová and Elisa Giovannetti
Cancers 2024, 16(24), 4260; https://doi.org/10.3390/cancers16244260 - 21 Dec 2024
Viewed by 1684
Abstract
Pancreatic cancer is an aggressive tumor with dismal prognosis. Neural invasion is one of the pathological hallmarks of pancreatic cancer. Peripheral nerves can modulate the phenotype and behavior of the malignant cells, as well as of different components of the tumor microenvironment, and [...] Read more.
Pancreatic cancer is an aggressive tumor with dismal prognosis. Neural invasion is one of the pathological hallmarks of pancreatic cancer. Peripheral nerves can modulate the phenotype and behavior of the malignant cells, as well as of different components of the tumor microenvironment, and thus affect tumor growth and metastasis. From a clinical point of view, neural invasion is translated into intractable pain and represents a predictor of tumor recurrence and poor prognosis. Several molecules are implicated in neural invasion and pain onset in PDAC, including neutrophins (e.g., NGF), chemokines, adhesion factors, axon-guidance molecules, different proteins, and neurotransmitters. In this review, we discuss the role of nerves within the pancreatic cancer microenvironment, highlighting how infiltrating nerve fibers promote tumor progression and metastasis, while tumor cells, in turn, drive nerve outgrowth in a reciprocal interaction that fuels tumor advancement. We outline key molecules involved in neural invasion in pancreatic cancer and, finally, explore potential therapeutic strategies to target neural invasion, aiming to both inhibit cancer progression and alleviate cancer-associated pain. Full article
(This article belongs to the Special Issue Clinical Applications of Molecular Subtyping of Pancreatic Cancer)
Show Figures

Figure 1

26 pages, 1512 KiB  
Review
Precision Targeting Strategies in Pancreatic Cancer: The Role of Tumor Microenvironment
by Nikolaos Vitorakis, Antonios N. Gargalionis, Kostas A. Papavassiliou, Christos Adamopoulos and Athanasios G. Papavassiliou
Cancers 2024, 16(16), 2876; https://doi.org/10.3390/cancers16162876 - 19 Aug 2024
Cited by 3 | Viewed by 2990
Abstract
Pancreatic cancer demonstrates an ever-increasing incidence over the last years and represents one of the top causes of cancer-associated mortality. Cells of the tumor microenvironment (TME) interact with cancer cells in pancreatic ductal adenocarcinoma (PDAC) tumors to preserve cancer cells’ metabolism, inhibit drug [...] Read more.
Pancreatic cancer demonstrates an ever-increasing incidence over the last years and represents one of the top causes of cancer-associated mortality. Cells of the tumor microenvironment (TME) interact with cancer cells in pancreatic ductal adenocarcinoma (PDAC) tumors to preserve cancer cells’ metabolism, inhibit drug delivery, enhance immune suppression mechanisms and finally develop resistance to chemotherapy and immunotherapy. New strategies target TME genetic alterations and specific pathways in cell populations of the TME. Complex molecular interactions develop between PDAC cells and TME cell populations including cancer-associated fibroblasts, myeloid-derived suppressor cells, pancreatic stellate cells, tumor-associated macrophages, tumor-associated neutrophils, and regulatory T cells. In the present review, we aim to fully explore the molecular landscape of the pancreatic cancer TME cell populations and discuss current TME targeting strategies to provide thoughts for further research and preclinical testing. Full article
(This article belongs to the Special Issue Clinical Applications of Molecular Subtyping of Pancreatic Cancer)
Show Figures

Figure 1

Back to TopTop